---
title: Virtual reality improves walking coordination
nct_id: NCT07250672
phase: NA
status: RECRUITING
sponsor: Abant Izzet Baysal University
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07250672"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07250672"
last_fetched: "2026-05-12T14:02:08.529Z"
source: "Parkinson's Pathways (curated)"
---
# Virtual reality improves walking coordination

**Goal (in five words):** Virtual reality improves walking coordination

**Official Title:** Examining the Effect of Action Observation Training Using Patient-Specific 3D Records in Parkinson's Patients

**Trial ID:** [NCT07250672](https://clinicaltrials.gov/study/NCT07250672)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Abant Izzet Baysal University
- **Target Enrollment:** 24 participants
- **Start Date:** 2025-12-15
- **Completion Date:** 2027-07-15
- **Conditions:** Parkinson Disease, Virtual Reality, Action Obervation Training, Immersive Virtual Reality, 3d Recording
- **Interventions:** Patient-Specific VR Action Observation Training, Healthy-Model VR Action Observation Training
- **Intervention Types:** OTHER

## Summary For Families

The goal is to help people with mild to moderate Parkinson's improve walking and everyday motor skills by strengthening the brain circuits that plan and mirror movement. The approach uses immersive virtual reality so you watch 3D recordings, either of your own movements or of a healthy model, to activate motor learning pathways and encourage smoother, more coordinated actions; this is a non-drug rehab method used alongside your usual antiparkinsonian medications, not a replacement for levodopa. The trial is looking for people aged 50 to 85 with Parkinson's at Hoehn and Yahr stage 3 or lower who can walk independently and are on stable antiparkinsonian meds, excluding those with other neurological disorders, recent medication changes, significant 3D vision problems, or pronounced simulator sickness.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 85 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Voluntary agreement to participate in the study
* Clinical diagnosis of Parkinson's disease confirmed by a neurologist
* Ongoing treatment with antiparkinsonian medication
* Hoehn and Yahr (H-Y) stage ≤ 3
* Ability to walk independently

Exclusion Criteria:

* Presence of additional neurological disorders other than Parkinson's disease
* Change in medication dosage within the past month
* Score of ≥ 10 on the Simulator Sickness Questionnaire
* Presence of amblyopia, strabismus, or pathologies impairing focus, depth perception, or normal 3D vision
* Failure on the butterfly test of the Titmus stereotest (greater than 3,552 seconds of arc)
```

## Locations (1)

- Abant Izzet Baysal University Faculty of Health Science, Bolu, Bolu, Turkey (Türkiye) _(40.7358, 31.6061)_
  - ENES T Benli — (CONTACT) — +905387359268 — enestayyipbenli@gmail.com

## Central Contacts

- Enes T Benli, Ph.D — (CONTACT) — +905387359268 — enestayyipbenli@gmail.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07250672*  
*HTML version: https://parkinsonspathways.com/trial/NCT07250672*  
*Source data: https://clinicaltrials.gov/study/NCT07250672*